Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
Toxicity and antitumor effects of four compounds from the groups of triazoloacridinones and imidazoacridinones were evaluated in transplantable tumor systems in mice, including P388 leukemia, B16 melanoma and 2 colon adenocarcinomas C26 and C38. Tested compounds had moderate antileukemic activity but were active against B16 melanoma and 3 of them were very efficacious against colon tumors, providing high percentages of "cures". Toxicity for healthy mice, as well as antitumor activity, were found to depend on a treatment protocol. The compounds were better tolerated and gave higher antitumor effects when given as fractionated treatment. They displayed also sex-dependent toxicity and activity.
Kuśnierczyk
H
H
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
Chołody
W M
WM
Paradziej-Lukowicz
J
J
Radzikowski
C
C
Konopa
J
J
D000166:Acridines / Q000494:pharmacology* / Q000633:toxicity; D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D003110:Colonic Neoplasms / Q000188:drug therapy; D004354:Drug Screening Assays, Antitumor; D005260:Female; D007093:Imidazoles / Q000494:pharmacology / Q000633:toxicity; D007928:Lethal Dose 50; D007941:Leukemia P388 / Q000188:drug therapy; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D014230:Triazoles / Q000494:pharmacology / Q000633:toxicity
D000166:Acridines; D000970:Antineoplastic Agents; D007093:Imidazoles; D014230:Triazoles